With a broad portfolio of tumor markers for prostate.

Roche is developing new tests which will on the progression on the progression in cancer patients in the future. With a broad portfolio of tumor markers for prostate, colorectal, ovarian, pancreatic, lung, and a range of molecular oncology tests, we will continue leading provider of cancer focused treatments and diagnostics to be.

When Health Canada identified a potential safety concerns, Health Canada will take appropriate action This includes the communication safety for Canadians as necessary, ‘the agency said.Osteoporosis Journalism Award Listings closing two weeksmessages the International Osteoporosis Foundation 2005 Journalism Award with prizes worth USD the seventeenth near of only three weeks. Article about osteoporosis on mainstream media and particular medical Material, between 1 January to 31 be be publishes 2005 eligible. Entries are 31st to the be accepted.

An application form can visit the IOF website osteofound.org / press_centre / journalism_award. Extent, it Further information being see the IOF Press Room osteofound.org / press_centre / index.html you find.

1 Melton U, Chris Chilles O, Cooperstown C et al. How many women are osteoporosis? Journal of Bone Mineral Research, 1992; 7:1005-10 two canisters JA et al. Osteoporosis International, 2000, 11:669-674 3 Melton LJ, BMD and risk of fractures in men.